Divis Laboratories Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
5960.00 +63.85 (1.08%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5884.55
Today’s High
6002.6
52 Week Low
3350.05
52 Week High
6276.2
5977.10 +76.25 (1.29%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5880.1
Today’s High
6004.5
52 Week Low
3350
52 Week High
6275.85
Key Metrics
- Market Cap (In Cr) 156649
- Beta 0.54
- Div. Yield (%) 0.51
- P/B 11.54
- TTM P/E 78.73
- Peg Ratio -12.33
- Sector P/E 40.69
- D/E 0
- Open Price 5944.95
- Prev Close 5896.15
Divis Laboratories Analysis
Price Analysis
-
1 Week0.02%
-
3 Months24.93%
-
6 Month46.91%
-
YTD51.15%
-
1 Year60.66%
Risk Meter
- 26% Low risk
- 26% Moderate risk
- 26% Balanced Risk
- 26% High risk
- 26% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 2
- Buy
- 4
- 4
- 3
- 3
- Hold
- 5
- 5
- 6
- 6
- Sell
- 5
- 5
- 5
- 5
- Strong Sell
- 6
- 6
- 6
- 6
- Total
- 23
- 23
- 23
- 22
Divis Laboratories News
Top events on Nov 9: Asian Paints, Aurobindo Pharma Q2 results, Uttarakhand UCC
2 min read . 09 Nov 2024HDFC Asset Management Company, Divis Laboratories & others hit 52 week high today ; Do you own any?
4 min read . 15 Oct 2024Divis Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 7845
- Selling/ General/ Admin Expenses Total
- 1094
- Depreciation/ Amortization
- 378
- Other Operating Expenses Total
- 1417
- Total Operating Expense
- 6018
- Operating Income
- 1827
- Net Income Before Taxes
- 2163
- Net Income
- 1600
- Diluted Normalized EPS
- 60.27
- Period
- 2024
- Total Assets
- 15470
- Total Liabilities
- 1899
- Total Equity
- 13571
- Tangible Book Valueper Share Common Eq
- 511.06
- Period
- 2024
- Cashfrom Operating Activities
- 1261
- Cashfrom Investing Activities
- -269
- Cashfrom Financing Activities
- -799
- Net Changein Cash
- 193
- Period
- 2023
- Total Revenue
- 7767.51
- Selling/ General/ Admin Expenses Total
- 1654.4
- Depreciation/ Amortization
- 343.18
- Total Operating Expense
- 5741.74
- Operating Income
- 2025.77
- Net Income Before Taxes
- 2368.63
- Net Income
- 1823.38
- Diluted Normalized EPS
- 68.72
- Period
- 2023
- Total Assets
- 14438.77
- Total Liabilities
- 1671.68
- Total Equity
- 12767.09
- Tangible Book Valueper Share Common Eq
- 480.73
- Period
- 2023
- Cashfrom Operating Activities
- 2459.73
- Cashfrom Investing Activities
- -2707.62
- Cashfrom Financing Activities
- -797.17
- Net Changein Cash
- -1045.06
- Period
- 2022
- Total Revenue
- 8959.83
- Selling/ General/ Admin Expenses Total
- 1541.48
- Depreciation/ Amortization
- 311.51
- Total Operating Expense
- 5387.35
- Operating Income
- 3572.48
- Net Income Before Taxes
- 3683.5
- Net Income
- 2960.45
- Diluted Normalized EPS
- 111.58
- Period
- 2022
- Total Assets
- 13374.71
- Total Liabilities
- 1646.53
- Total Equity
- 11728.18
- Tangible Book Valueper Share Common Eq
- 441.51
- Period
- 2022
- Cashfrom Operating Activities
- 1911.8
- Cashfrom Investing Activities
- -2194.92
- Cashfrom Financing Activities
- -532.44
- Net Changein Cash
- -815.56
- Period
- 2021
- Total Revenue
- 6969.4
- Selling/ General/ Admin Expenses Total
- 1306
- Depreciation/ Amortization
- 255.59
- Total Operating Expense
- 4354.71
- Operating Income
- 2614.69
- Net Income Before Taxes
- 2666.04
- Net Income
- 1984.29
- Diluted Normalized EPS
- 74.91
- Period
- 2021
- Total Assets
- 10774.07
- Total Liabilities
- 1479.46
- Total Equity
- 9294.61
- Tangible Book Valueper Share Common Eq
- 349.93
- Period
- 2021
- Cashfrom Operating Activities
- 1946.93
- Cashfrom Investing Activities
- 75.13
- Cashfrom Financing Activities
- -34.89
- Net Changein Cash
- 1987.17
- Period
- 2020
- Total Revenue
- 5394.42
- Selling/ General/ Admin Expenses Total
- 1061.8
- Depreciation/ Amortization
- 186.24
- Total Operating Expense
- 3754.2
- Operating Income
- 1640.22
- Net Income Before Taxes
- 1819.46
- Net Income
- 1376.54
- Diluted Normalized EPS
- 51.95
- Period
- 2020
- Total Assets
- 8535.7
- Total Liabilities
- 1225.78
- Total Equity
- 7309.92
- Tangible Book Valueper Share Common Eq
- 275.22
- Period
- 2020
- Cashfrom Operating Activities
- 1215.94
- Cashfrom Investing Activities
- -83.47
- Cashfrom Financing Activities
- -1091.42
- Net Changein Cash
- 41.05
- Period
- 2019
- Total Revenue
- 4946.26
- Selling/ General/ Admin Expenses Total
- 881.55
- Depreciation/ Amortization
- 168.9
- Total Operating Expense
- 3240.75
- Operating Income
- 1705.51
- Net Income Before Taxes
- 1855.07
- Net Income
- 1352.74
- Diluted Normalized EPS
- 50.99
- Period
- 2019
- Total Assets
- 8038.25
- Total Liabilities
- 1081.1
- Total Equity
- 6957.15
- Tangible Book Valueper Share Common Eq
- 261.92
- Period
- 2019
- Cashfrom Operating Activities
- 954.3
- Cashfrom Investing Activities
- -685.4
- Cashfrom Financing Activities
- -245.94
- Net Changein Cash
- 22.96
- Period
- 2018
- Total Revenue
- 3912.78
- Selling/ General/ Admin Expenses Total
- 757.07
- Depreciation/ Amortization
- 142.49
- Total Operating Expense
- 2787.3
- Operating Income
- 1125.48
- Net Income Before Taxes
- 1231.33
- Net Income
- 877.01
- Diluted Normalized EPS
- 33.2
- Period
- 2018
- Total Assets
- 6785.85
- Total Liabilities
- 861.05
- Total Equity
- 5924.8
- Tangible Book Valueper Share Common Eq
- 222.94
- Period
- 2018
- Cashfrom Operating Activities
- 775.86
- Cashfrom Investing Activities
- -478.3
- Cashfrom Financing Activities
- -314.16
- Net Changein Cash
- -16.6
- Period
- 2024-09-30
- Total Revenue
- 2338
- Selling/ General/ Admin Expenses Total
- 304
- Depreciation/ Amortization
- 99
- Other Operating Expenses Total
- 349
- Total Operating Expense
- 1721
- Operating Income
- 617
- Net Income Before Taxes
- 722
- Net Income
- 510
- Diluted Normalized EPS
- 19.2
- Period
- 2024-09-30
- Total Assets
- 15586
- Total Liabilities
- 1869
- Total Equity
- 13717
- Tangible Book Valueper Share Common Eq
- 516.56
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 926
- Cashfrom Investing Activities
- -459
- Cashfrom Financing Activities
- -792
- Net Changein Cash
- -325
- Period
- 2024-06-30
- Total Revenue
- 2118
- Selling/ General/ Admin Expenses Total
- 292
- Depreciation/ Amortization
- 97
- Other Operating Expenses Total
- 350
- Total Operating Expense
- 1592
- Operating Income
- 526
- Net Income Before Taxes
- 604
- Net Income
- 430
- Diluted Normalized EPS
- 16.2
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2303
- Selling/ General/ Admin Expenses Total
- 297
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 373
- Total Operating Expense
- 1667
- Operating Income
- 636
- Net Income Before Taxes
- 713
- Net Income
- 538
- Diluted Normalized EPS
- 20.25
- Period
- 2024-03-31
- Total Assets
- 15470
- Total Liabilities
- 1899
- Total Equity
- 13571
- Tangible Book Valueper Share Common Eq
- 511.06
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1261
- Cashfrom Investing Activities
- -269
- Cashfrom Financing Activities
- -799
- Net Changein Cash
- 193
- Period
- 2023-12-31
- Total Revenue
- 1855
- Selling/ General/ Admin Expenses Total
- 268
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 369
- Total Operating Expense
- 1461
- Operating Income
- 394
- Net Income Before Taxes
- 489
- Net Income
- 358
- Diluted Normalized EPS
- 13.5
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1909
- Selling/ General/ Admin Expenses Total
- 266
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 354
- Total Operating Expense
- 1525
- Operating Income
- 384
- Net Income Before Taxes
- 469
- Net Income
- 348
- Diluted Normalized EPS
- 13.11
- Period
- 2023-09-30
- Total Assets
- 14283
- Total Liabilities
- 1606
- Total Equity
- 12677
- Tangible Book Valueper Share Common Eq
- 477.42
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 539
- Cashfrom Investing Activities
- 122
- Cashfrom Financing Activities
- -798
- Net Changein Cash
- -137
- Period
- 2023-06-30
- Total Revenue
- 1778
- Selling/ General/ Admin Expenses Total
- 263
- Depreciation/ Amortization
- 93
- Other Operating Expenses Total
- 323
- Total Operating Expense
- 1367
- Operating Income
- 411
- Net Income Before Taxes
- 492
- Net Income
- 356
- Diluted Normalized EPS
- 13.41
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1950.77
- Selling/ General/ Admin Expenses Total
- 257.64
- Depreciation/ Amortization
- 87.02
- Other Operating Expenses Total
- 373.75
- Total Operating Expense
- 1545.99
- Operating Income
- 404.78
- Net Income Before Taxes
- 466.48
- Net Income
- 320.97
- Diluted Normalized EPS
- 12.09
- Period
- 2023-03-31
- Total Assets
- 14438.77
- Total Liabilities
- 1671.68
- Total Equity
- 12767.09
- Tangible Book Valueper Share Common Eq
- 480.73
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2459.73
- Cashfrom Investing Activities
- -2707.62
- Cashfrom Financing Activities
- -797.17
- Net Changein Cash
- -1045.06
- Period
- 2022-12-31
- Total Revenue
- 1707.68
- Selling/ General/ Admin Expenses Total
- 238.88
- Depreciation/ Amortization
- 86.77
- Other Operating Expenses Total
- 320.97
- Total Operating Expense
- 1386.17
- Operating Income
- 321.51
- Net Income Before Taxes
- 435.63
- Net Income
- 306.8
- Diluted Normalized EPS
- 11.56
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Divis Laboratories Technical
Moving Average
SMA
- 5 Day5796.67
- 10 Day5852.17
- 20 Day5838.22
- 50 Day5699
- 100 Day5222.46
- 300 Day4535.04
Divis Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1771.65
- -3.55
- -0.2
- 1960.2
- 1180.1
- 425078.18
- Divis Laboratories
- 5960
- 63.85
- 1.08
- 6276.2
- 3350.05
- 158219.27
- Cipla
- 1463
- -8.35
- -0.57
- 1702
- 1165.1
- 118121.88
- Torrent Pharmaceuticals
- 3105.4
- 10.6
- 0.34
- 3589.95
- 2025
- 105105.37
- Dr Reddys Laboratories
- 1194.55
- -19.4
- -1.6
- 1420.2
- 1074.35
- 19892.66
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 42.58
- 6.7
- 11.27
- 14.23
- Divis Laboratories
- 97.72
- 11.54
- 18.97
- 26.38
- Cipla
- 27.37
- 4.45
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 65.33
- 15.28
- 20.64
- 13.18
- Dr Reddys Laboratories
- 18.36
- 3.58
- 16.73
- 14.63
Divis Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 09-Nov-24
- Quarterly Results
- 03-Aug-24
- Quarterly Results
- 25-May-24
- Audited Results & Dividend
- 10-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 20-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- 07-Nov-22
- Quarterly Results
- 12-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 12-Aug-24
- 15-Jul-24
- AGM
- 06-Apr-24
- 04-Mar-24
- POM
- 28-Aug-23
- 20-May-23
- AGM
- 22-Aug-22
- 04-Jul-22
- AGM
- 28-Mar-22
- 24-Feb-22
- POM
- 30-Aug-21
- 02-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-24
- 02-Aug-24
- 02-Aug-24
- 30
- 22-May-23
- 11-Aug-23
- 11-Aug-23
- 30
- 23-May-22
- 12-Aug-22
- 11-Aug-22
- 30
- 31-May-21
- -
- 17-Aug-21
- 20